Pleurotus ostreatus mushroom contains important bioactive compounds and has several biological activities; however, mushroom growing substrates have major influence on chemical and functional characteristics of the mushroom. Hence, the study aimed to evaluate the influence of supplementing mushroom growing substrates with wheat bran (WB) towards yield/productivity, bioactive compounds, and antimicrobial and antioxidant activity of P. ostreatus. The mushroom was cultivated on sugarcane substrates supplemented with increasing levels of WB (020). The mushroom extracts were screened for bioactive compounds using gas chromatography-mass spectrometry (GC-MS). Antimicrobial activity was carried out using microplate assay, while antioxidant potential was investigated using reducing power assay. The addition of supplements on mushroom growing substrates had an influence on mushroom yield; hence, higher supplementation (18 and 20) produced higher yield. The GC-MS revealed several bioactive compounds with known activity, such as vitamin E, phenol, fatty acids, and terpenoids. Concentration-dependent antioxidant activity was observed; hence, extracts at higher concentrations gave significantly higher reducing power. The P. ostreatus extract had antimicrobial activity against all the tested organisms, with S. aureus showing high susceptibility to most of the extracts. However, mushrooms grown on bagasse substrates supplemented with 14 (0.02mg/ml) and 20 WB (0.08mg/ml) proved to have better antimicrobial activity on Escherichia coli. The difference in susceptibility demonstrates that substrates type and composition could have an influence on bioactive compounds found within mushrooms, also influencing medicinal properties of edible mushroom. Thus, supplementing mushroom growing substrates not only improve yield, but also can contribute to bioactive compounds with medicinal potential.

In recent years, the potential of pathogenic bacteria to acquire resistance to a variety of antimicrobial drugs has developed significantly due to the indiscriminate exposure of a number of antibiotic compounds. The purpose of this study is to determine the antibacterial capabilities and activities of crude Pleurotus ostreatus extracts against Staphylococcus aureus (ATCC 25923), Escherichia coli (ATCC 25922), Neisseria gonorrhoeae (ATCC 49926), and nine multidrug-resistant clinical isolates of Neisseria gonorrhoeae. All of these isolates exhibited sensitivity to azithromycin and ceftriaxone, while the majority of antibiotic resistance was seen against penicillin G, sulphonamide, and ciprofloxacin. Fifty percent of the isolates exhibited absolute resistance to both sulphonamide and ciprofloxacin, whereas 40 of the isolates displayed absolute resistance to penicillin G. The antibacterial activity of P. ostreatus extracts examined in this investigation varied within the same species of microorganisms. Extract B and D, extracted in the presence of 20 wheat bran bagasse and 20 maize flour bagasse, respectively, had exceptional antibacterial activity against all target isolates examined. We observed the lowest concentration of antibacterial agent required to inhibit the target bacteria to be between 1×10⁻³mg/ml and 1×10⁻⁶mg/ml with an estimated probability of 0.30769, a lower 95 confidence interval (CI) of 0.126807, an upper 95 CI of 0.576307, an estimated probability of 0.15385, a lower 95 CI of 0.043258, and an upper 95 CI, respectively. The MBC of 1×10⁻³mg/ml was seen to eliminate 31 of the target bacteria. This dose was the most inhibitive. The antibacterial activity of all the extracts examined in the current study exhibited some degree of efficacy against both clinical isolates and standard strains. However, the majority of clinically isolated bacteria exhibited greater resistance to the extracts.

Pleurotus mushrooms are valuable food supplements with health and environmental restorative potential. In this paper, we sought to evaluate the biological activities and profile the bioactive compounds found in Pleurotus ostreatus cultivated from agro-waste supplemented with maize flour. We investigated carbon to nitrogen (C/N), antimicrobial, antioxidant, and antimalarial potential for the varying supplementation during mushroom cultivation. GCMS was utilized for screening bioactive compounds found in P. ostreatus. Changes in supplementation directly correlate with changes in compound profiling. Nonetheless, some compounds were found to be common amongst the tested mushrooms, including pentadecanoic acid; 9,12-octadecadienoic acid, methyl ester; pentadecanoic acid, methyl ester; octadecanoic acid; and diisooctyl phthalate. The highest antimicrobial potential against Gram-positive Staphylococcus aureus was observed when maize flour supplements were increased to 12 and 18. Our data demonstrated that the observed antioxidant (DPPH, ABTS, and reducing power) and antimicrobial activity could emanate from various supplementation conditions. Furthermore, supplementation has an impact on the mushroom yield and phytochemical profiles of the produced mushroom.

Type 2 Diabetes Mellitus (T2DM) is increasingly affecting individuals across various age groups due to inadequate insulin action and secretion. It has become the leading cause of mortality worldwide, with an estimated 9.3% of the global population currently affected. Recent epigenetic studies have shown that variations such as DNA methylation and histone modifications are implicated in the development of T2DM. However, epigenetically related conditions are known to be reversible, which could potentially pave the way for predicting and treating T2DM. This has led to the development of epigenetic modifier drugs, including histone deacetylase inhibitors (HDACi), histone acetyltransferase inhibitors (HATi), protein arginine methyltransferase inhibitors (PRMTi), DNA methyltransferase inhibitors (DNMTi), histone demethylating inhibitors (HDMi), and sirtuin-activating compounds (STAC). A major challenge with these epigenetic drugs is that only a few have been approved for treating metabolic diseases due to their potential to negatively impact off-target genes. The low specificity of these drugs can lead to side effects and increased toxicity, contributing to complex diseases such as cancer. Hence, gaining a comprehensive understanding of the epigenetic mechanisms underlying metabolic diseases can provide new insights and strategies for preventing, diagnosing, and treating metabolic disorders, such as T2DM. This review summarizes the epigenetic variations in T2DM, pharmaco-epigenetics, and the challenges surrounding epigenetics. This provides basic insight into the discovery of novel drug targets, which can lead to the development of epigenetic therapies for T2DM. Hence, the reversible nature of epigenetic variations retains hope for future novel strategies to combat T2DM.